Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazax compliance study with early versus delayed Memozax use in adults with grass pollen allergic rhinoconjunctivitis
2006-004820-35Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Mar 2007
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of phleum pratense allergen extract in allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR) (2 arms), sponsored by ALK-Abelló. Primary endpoint: Treatment compliance. Started Mar 2007; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2006-004820-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004820-35.